Notal Vision announced the completion of 6 million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD, according to a company news release.
ForeseeHome uses a patented technology, Preferential Hyperacuity Perimetry (PHP), that can identify minute changes in the central 14 degrees of visual field before the patient has any visual symptoms. During the test, which takes about 3 minutes, the central macula is evaluated for changes in metamorphopsia, distortion of the vision, caused by the onset of fluid in or under the retina. ForeseeHome testing results are sent to the Notal Vision Diagnostic Clinic (NVDC) via a cloud-based ecosystem. If there is a significant change in metamorphopsia, the adaptive test will generate an alert which is provided to the patient’s eye doctor by the NVDC. The patient is then evaluated by their doctor for progression from intermediate dry AMD to wet AMD.
ForeseeHome is the first home diagnostic product built on the NVDC infrastructure. The company is developing a second product, a home-based optical coherence tomography (OCT) system, that will also leverage the NVDC infrastructure.
“The home OCT system will allow patients to perform self-operated home testing, and a proprietary artificial intelligence-based algorithm will identify, localize, and quantify fluid associated with retinal vascular diseases. The NVDC will then generate a fluid alert to the doctor, indicating the need to evaluate the Home OCT images and the patient,” Susan Orr, OD, Chief Executive Officer of Notal Vision, said in a news release. “We seek to lead the ophthalmic home diagnostic monitoring category, and our NVDC infrastructure helps move eye care towards individualized and optimized retinal disease management.”